CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial demonstrates disease control in relapsed renal cell carcinoma, suggesting CAR T-cell efficacy in solid tumors.
Key Points
- Eighty-one point three percent of patients achieved disease control, marking a significant advancement in treatment.
- In a phase I trial, CTX130 showed strong preclinical proliferation and cytotoxicity against RCC tumors.
- Assessment using a next-generation CAR T construct could improve expansion and efficacy based on prior preclinical work in the field of solid tumors. 3-year durable complete response was observed in one patient, highlighting the approach's potential.
Cite This Study
Pal et al. (2024) studied this question.